Selected research
Market Structure
Global Immune Thrombocytopenia Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Immune Thrombocytopenia Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The US & Canada market for Immune Thrombocytopenia Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Immune Thrombocytopenia Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Immune Thrombocytopenia Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Immune Thrombocytopenia Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Immune Thrombocytopenia Drugs include Novartis AG, Merck & Co., Inc., Amgen Inc., Rigel Pharmaceuticals Inc., Horizon Therapeutics Plc and CSL Ltd., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Includes
This report provides an overview of the global Immune Thrombocytopenia Drugs market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Immune Thrombocytopenia Drugs and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Immune Thrombocytopenia Drugs revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Immune Thrombocytopenia Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.
Immune Thrombocytopenia Drugs Segment by Company
Novartis AG
Merck & Co., Inc.
Amgen Inc.
Rigel Pharmaceuticals Inc.
Horizon Therapeutics Plc
CSL Ltd.
Immune Thrombocytopenia Drugs Segment by Type
Intravenous Immunoglobins (IVIGs)
Corticosteroids
Thrombopoietin Receptor Agonists (TPO-RAs)
Other Drugs
Immune Thrombocytopenia Drugs Segment by Application
Hospitals and Diagnostic Centers
Academic Institutes and Research Organizations
Biotechnology and Pharmaceutical Companies
Immune Thrombocytopenia Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Immune Thrombocytopenia Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Immune Thrombocytopenia Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Immune Thrombocytopenia Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Immune Thrombocytopenia Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Immune Thrombocytopenia Drugs industry.
Chapter 3: Detailed analysis of Immune Thrombocytopenia Drugs companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Immune Thrombocytopenia Drugsrevenue, gross margin, and recent development, etc.
Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 8: Europe by type, by application and by country, revenue for each segment.
Chapter 9: China by type, and by application, revenue for each segment.
Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.
Chapter 12: Concluding Insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Intravenous Immunoglobins (IVIGs)
- Corticosteroids
- Thrombopoietin Receptor Agonists (TPO-RAs)
- Other Drugs
Applications
- Hospitals and Diagnostic Centers
- Academic Institutes and Research Organizations
- Biotechnology and Pharmaceutical Companies
Companies covered
- Novartis AG
- Merck & Co., Inc.
- Amgen Inc.
- Rigel Pharmaceuticals Inc.
- Horizon Therapeutics Plc
- CSL Ltd.
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Market Analysis by Type
- 1.2.1 Global Immune Thrombocytopenia Drugs Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
- 1.2.2 Intravenous Immunoglobins (IVIGs)
- 1.2.3 Corticosteroids
- 1.2.4 Thrombopoietin Receptor Agonists (TPO-RAs)
- 1.2.5 Other Drugs
- 1.3 Market Analysis by Application
- 1.3.1 Global Immune Thrombocytopenia Drugs Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
- 1.3.2 Hospitals and Diagnostic Centers
- 1.3.3 Academic Institutes and Research Organizations
- 1.3.4 Biotechnology and Pharmaceutical Companies
- 1.4 Global Market Growth Prospects
- 1.5 Global Immune Thrombocytopenia Drugs Growth Trends by Region
- 1.5.1 Global Immune Thrombocytopenia Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 1.5.2 Immune Thrombocytopenia Drugs Market Size by Region (2021-2026)
- 1.5.3 Immune Thrombocytopenia Drugs Market Size by Region (2027-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
- 1.8 Years Considered
2 Global Immune Thrombocytopenia Drugs Market Dynamics
- 2.1 Immune Thrombocytopenia Drugs Industry Trends
- 2.2 Immune Thrombocytopenia Drugs Industry Drivers
- 2.3 Immune Thrombocytopenia Drugs Industry Opportunities and Challenges
- 2.4 Immune Thrombocytopenia Drugs Industry Restraints
3 Competitive Landscape by Company
- 3.1 Global Immune Thrombocytopenia Drugs Revenue by Company (2021-2026)
- 3.2 Global Immune Thrombocytopenia Drugs Players Revenue Ranking, 2024 VS 2025 VS 2026
- 3.3 Global Immune Thrombocytopenia Drugs Key Company Head office and Area Served
- 3.4 Global Immune Thrombocytopenia Drugs Company, Product Type & Application
- 3.5 Global Immune Thrombocytopenia Drugs Company Establishment Date
- 3.6 Market Competitive Analysis
- 3.6.1 Global Immune Thrombocytopenia Drugs Market CR5 and HHI
- 3.6.2 Global Top 5 and 10 Immune Thrombocytopenia Drugs Players Market Share by Revenue in 2025
- 3.6.3 2025 Immune Thrombocytopenia Drugs Tier 1, Tier 2, and Tier 3
4 Immune Thrombocytopenia Drugs Market by Type
- 4.1 Global Immune Thrombocytopenia Drugs Market Size by Type (2021 VS 2025 VS 2032)
- 4.2 Global Immune Thrombocytopenia Drugs Market Size by Type (2021-2032)
- 4.3 Global Immune Thrombocytopenia Drugs Market Size Share by Type (2021-2032)
5 Immune Thrombocytopenia Drugs Market by Application
- 5.1 Global Immune Thrombocytopenia Drugs Market Size by Application (2021 VS 2025 VS 2032)
- 5.2 Global Immune Thrombocytopenia Drugs Market Size by Application (2021-2032)
- 5.3 Global Immune Thrombocytopenia Drugs Market Size Share by Application (2021-2032)
6 Company Profiles
- 6.1 Novartis AG
- 6.1.1 Novartis AG Company Information
- 6.1.2 Novartis AG Business Overview
- 6.1.3 Novartis AG Immune Thrombocytopenia Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.1.4 Novartis AG Immune Thrombocytopenia Drugs Product Portfolio
- 6.1.5 Novartis AG Recent Developments
- 6.2 Merck & Co., Inc.
- 6.2.1 Merck & Co., Inc. Company Information
- 6.2.2 Merck & Co., Inc. Business Overview
- 6.2.3 Merck & Co., Inc. Immune Thrombocytopenia Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.2.4 Merck & Co., Inc. Immune Thrombocytopenia Drugs Product Portfolio
- 6.2.5 Merck & Co., Inc. Recent Developments
- 6.3 Amgen Inc.
- 6.3.1 Amgen Inc. Company Information
- 6.3.2 Amgen Inc. Business Overview
- 6.3.3 Amgen Inc. Immune Thrombocytopenia Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.3.4 Amgen Inc. Immune Thrombocytopenia Drugs Product Portfolio
- 6.3.5 Amgen Inc. Recent Developments
- 6.4 Rigel Pharmaceuticals Inc.
- 6.4.1 Rigel Pharmaceuticals Inc. Company Information
- 6.4.2 Rigel Pharmaceuticals Inc. Business Overview
- 6.4.3 Rigel Pharmaceuticals Inc. Immune Thrombocytopenia Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.4.4 Rigel Pharmaceuticals Inc. Immune Thrombocytopenia Drugs Product Portfolio
- 6.4.5 Rigel Pharmaceuticals Inc. Recent Developments
- 6.5 Horizon Therapeutics Plc
- 6.5.1 Horizon Therapeutics Plc Company Information
- 6.5.2 Horizon Therapeutics Plc Business Overview
- 6.5.3 Horizon Therapeutics Plc Immune Thrombocytopenia Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.5.4 Horizon Therapeutics Plc Immune Thrombocytopenia Drugs Product Portfolio
- 6.5.5 Horizon Therapeutics Plc Recent Developments
- 6.6 CSL Ltd.
- 6.6.1 CSL Ltd. Company Information
- 6.6.2 CSL Ltd. Business Overview
- 6.6.3 CSL Ltd. Immune Thrombocytopenia Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.6.4 CSL Ltd. Immune Thrombocytopenia Drugs Product Portfolio
- 6.6.5 CSL Ltd. Recent Developments
7 North America
- 7.1 North America Immune Thrombocytopenia Drugs Market Size (2021-2032)
- 7.2 North America Immune Thrombocytopenia Drugs Market Size by Type
- 7.2.1 North America Immune Thrombocytopenia Drugs Market Size by Type (2021-2026)
- 7.2.2 North America Immune Thrombocytopenia Drugs Market Size by Type (2027-2032)
- 7.2.3 North America Immune Thrombocytopenia Drugs Market Share by Type (2021-2032)
- 7.3 North America Immune Thrombocytopenia Drugs Market Size by Application
- 7.3.1 North America Immune Thrombocytopenia Drugs Market Size by Application (2021-2026)
- 7.3.2 North America Immune Thrombocytopenia Drugs Market Size by Application (2027-2032)
- 7.3.3 North America Immune Thrombocytopenia Drugs Market Share by Application (2021-2032)
- 7.4 North America Immune Thrombocytopenia Drugs Market Size by Country
- 7.4.1 North America Immune Thrombocytopenia Drugs Market Size by Country (2021 VS 2025 VS 2032)
- 7.4.2 North America Immune Thrombocytopenia Drugs Market Size by Country (2021-2026)
- 7.4.3 North America Immune Thrombocytopenia Drugs Market Size by Country (2027-2032)
- 7.4.4 North America Immune Thrombocytopenia Drugs Market Share by Country (2021-2032)
- 7.4.5 United States
- 7.4.6 Canada
- 7.4.7 Mexico
8 Europe
- 8.1 Europe Immune Thrombocytopenia Drugs Market Size (2021-2032)
- 8.2 Europe Immune Thrombocytopenia Drugs Market Size by Type
- 8.2.1 Europe Immune Thrombocytopenia Drugs Market Size by Type (2021-2026)
- 8.2.2 Europe Immune Thrombocytopenia Drugs Market Size by Type (2027-2032)
- 8.2.3 Europe Immune Thrombocytopenia Drugs Market Share by Type (2021-2032)
- 8.3 Europe Immune Thrombocytopenia Drugs Market Size by Application
- 8.3.1 Europe Immune Thrombocytopenia Drugs Market Size by Application (2021-2026)
- 8.3.2 Europe Immune Thrombocytopenia Drugs Market Size by Application (2027-2032)
- 8.3.3 Europe Immune Thrombocytopenia Drugs Market Share by Application (2021-2032)
- 8.4 Europe Immune Thrombocytopenia Drugs Market Size by Country
- 8.4.1 Europe Immune Thrombocytopenia Drugs Market Size by Country (2021 VS 2025 VS 2032)
- 8.4.2 Europe Immune Thrombocytopenia Drugs Market Size by Country (2021-2026)
- 8.4.3 Europe Immune Thrombocytopenia Drugs Market Size by Country (2027-2032)
- 8.4.4 Europe Immune Thrombocytopenia Drugs Market Share by Country (2021-2032)
- 8.4.5 Germany
- 8.4.6 France
- 8.4.7 U.K.
- 8.4.8 Italy
- 8.4.9 Russia
- 8.4.10 Nordic Countries
9 China
- 9.1 China Immune Thrombocytopenia Drugs Market Size (2021-2032)
- 9.2 China Immune Thrombocytopenia Drugs Market Size by Type
- 9.2.1 China Immune Thrombocytopenia Drugs Market Size by Type (2021-2026)
- 9.2.2 China Immune Thrombocytopenia Drugs Market Size by Type (2027-2032)
- 9.2.3 China Immune Thrombocytopenia Drugs Market Share by Type (2021-2032)
- 9.3 China Immune Thrombocytopenia Drugs Market Size by Application
- 9.3.1 China Immune Thrombocytopenia Drugs Market Size by Application (2021-2026)
- 9.3.2 China Immune Thrombocytopenia Drugs Market Size by Application (2027-2032)
- 9.3.3 China Immune Thrombocytopenia Drugs Market Share by Application (2021-2032)
10 Asia (Excluding China)
- 10.1 Asia Immune Thrombocytopenia Drugs Market Size (2021-2032)
- 10.2 Asia Immune Thrombocytopenia Drugs Market Size by Type
- 10.2.1 Asia Immune Thrombocytopenia Drugs Market Size by Type (2021-2026)
- 10.2.2 Asia Immune Thrombocytopenia Drugs Market Size by Type (2027-2032)
- 10.2.3 Asia Immune Thrombocytopenia Drugs Market Share by Type (2021-2032)
- 10.3 Asia Immune Thrombocytopenia Drugs Market Size by Application
- 10.3.1 Asia Immune Thrombocytopenia Drugs Market Size by Application (2021-2026)
- 10.3.2 Asia Immune Thrombocytopenia Drugs Market Size by Application (2027-2032)
- 10.3.3 Asia Immune Thrombocytopenia Drugs Market Share by Application (2021-2032)
- 10.4 Asia Immune Thrombocytopenia Drugs Market Size by Country
- 10.4.1 Asia Immune Thrombocytopenia Drugs Market Size by Country (2021 VS 2025 VS 2032)
- 10.4.2 Asia Immune Thrombocytopenia Drugs Market Size by Country (2021-2026)
- 10.4.3 Asia Immune Thrombocytopenia Drugs Market Size by Country (2027-2032)
- 10.4.4 Asia Immune Thrombocytopenia Drugs Market Share by Country (2021-2032)
- 10.4.5 Japan
- 10.4.6 South Korea
- 10.4.7 Taiwan
- 10.4.8 Southeast Asia
- 10.4.9 India
- 10.4.10 Australia
11 South America, Middle East & Africa
- 11.1 South America, Middle East & Africa Immune Thrombocytopenia Drugs Market Size (2021-2032)
- 11.2 South America, Middle East & Africa Immune Thrombocytopenia Drugs Market Size by Type
- 11.2.1 South America, Middle East & Africa Immune Thrombocytopenia Drugs Market Size by Type (2021-2026)
- 11.2.2 South America, Middle East & Africa Immune Thrombocytopenia Drugs Market Size by Type (2027-2032)
- 11.2.3 South America, Middle East & Africa Immune Thrombocytopenia Drugs Market Share by Type (2021-2032)
- 11.3 South America, Middle East & Africa Immune Thrombocytopenia Drugs Market Size by Application
- 11.3.1 South America, Middle East & Africa Immune Thrombocytopenia Drugs Market Size by Application (2021-2026)
- 11.3.2 South America, Middle East & Africa Immune Thrombocytopenia Drugs Market Size by Application (2027-2032)
- 11.3.3 South America, Middle East & Africa Immune Thrombocytopenia Drugs Market Share by Application (2021-2032)
- 11.4 South America, Middle East & Africa Immune Thrombocytopenia Drugs Market Size by Country
- 11.4.1 South America, Middle East & Africa Immune Thrombocytopenia Drugs Market Size by Country (2021 VS 2025 VS 2032)
- 11.4.2 South America, Middle East & Africa Immune Thrombocytopenia Drugs Market Size by Country (2021-2026)
- 11.4.3 South America, Middle East & Africa Immune Thrombocytopenia Drugs Market Size by Country (2027-2032)
- 11.4.4 South America, Middle East & Africa Immune Thrombocytopenia Drugs Market Share by Country (2021-2032)
- 11.4.5 Brazil
- 11.4.6 South Africa
- 11.4.7 Saudi Arabia
- 11.4.8 Turkey
- 11.4.9 Argentina
- 11.4.9 UAE
- 11.4.9 Egypt
- 11.4.9 Chile
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
- 13.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst